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Abstract This study aims to determine whether abdominal
microbial profiles in early severe secondary peritonitis are
associated with ongoing infection or death. The study is
performed within a randomized study comparing two
surgical treatment strategies in patients with severe second-
ary peritonitis (n=229). The microbial profiles of cultures
retrieved from initial emergency laparotomy were tested
with logistic regression analysis for association with
‘ongoing infection needing relaparotomy’ and in-hospital
death. No microbial profile or the presence of yeast or
Pseudomonas spp. was related to the risk of ongoing
infection needing relaparotomy. Resistance to empiric
therapy for gram positive cocci and coliforms was
moderately associated with ongoing abdominal infection
(OR 3.43 95%CI 0.95–12.38 and OR 7.61, 95%CI 0.75–
76.94). Presence of only gram positive cocci, predominant-
ly Enterococcus spp, was borderline independently associ-
ated with in-hospital death (OR 3.69, 95%CI 0.99–13.80).
In secondary peritonitis microbial profiles do not predict
ongoing abdominal infection after initial emergency lapa-
rotomy. However, the moderate association of ongoing
infection with resistance to the empiric therapy compels to
more attention for resistance when selecting empiric
antibiotic coverage.
Introduction
Abdominal sepsis is an often encountered, severe condition,
treated by a multidisciplinary team of surgeons, intensive
care specialists, radiologists and microbiologists. Surgical
source control by elimination of the infectious focus is the
main constituent of treatment. However, organ failure
support and additional microbial therapy are indispensable
features of treatment [1]. Especially very early antibiotic
intervention is propagated as effective in reducing mortality
in sepsis [2–4].
Previous studies have focused on identification of
clinical and laboratory variables of value for identification
of patients at high risk for ongoing infection [5–17]. In
particular post-operative physiological parameters are help-
ful in identifying abdominal sepsis patients in need of a
relaparotomy rather than peritonitis and operative character-
istics [14]. However, the relation between the microbial
profile of peritoneal infection and patient outcome has not
been studied extensively in a prospective setting. If there is
a relation, this could have consequences for the choice of
the empiric broad spectrum antibiotic coverage aimed at
possible pathogens in the intestinal flora [18, 19].
The clinical management consequences of abdominal
fluid cultures obtained at initial emergency laparotomy is
often questioned. Culture results including susceptibility
patterns are first available after at least 48–72 hours, and
the retrieved species may not vary that much. Furthermore,
it is stated that the antibiotic treatment window really
affecting patient outcome lies in the first few hours,
stressing the importance of adequate empiric regimes [20].
Moreover, some secondary peritonitis patients require a
relaparotomy because of clinical suspicion of ongoing
infection. This decision is usually made before culture
results become available. However, if index cultures are
predictive of a complicated course with (multiple) relapar-
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profile may influence treatment decision and thereby affect
outcome. The aim of this study is to determine whether
abdominal microbial profiles in early secondary peritonitis
are predictive of the course of disease.
Methods
Design and eligibility
All patients from the RELAP trial (ISRCTN51729393)
were enrolled in this study (n=229). The RELAP trial was
a randomized controlled clinical trial comparing two main
surgical strategies for severe secondary peritonitis following
the initial emergency laparotomy: on-demand relaparotomy
(n=114) versus planned relaparotomy (n=115) [12].
Patients were eligible with an APACHE-II score >10 and
diagnosed with abdominal sepsis, verified during surgery,
caused by perforation or infection of a visceral organ or
ischemia/necrosis of part of the gastrointestinal tract due to
strangulation or postoperative peritoneal infection. Details
on design and patient inclusion have been described
elsewhere [12].
‘On-demand’ relaparotomy was performed only in case
of no clinical improvement or in case of clinical deteriora-
tion, monitored by physiological, laboratory and radiology
parameters. Planned relaparotomy was performed every 36
to 48 hours until the abdomen was macroscopically clean at
the beginning of the final relaparotomy. All eligible patients
were enrolled at two academic and seven major teaching
hospitals. The study was approved by the Medical Ethics
Committees of all participating hospitals.
Outcome
The aim of the present study was to evaluate whether
specific microbial profiles are associated with ongoing
infection needing relaparotomy and/or with in-hospital
death. ‘Ongoing infection needing relaparotomy’ points to
residual abdominal infection or a new infectious focus in
the abdominal cavity. If patients did not receive a
relaparotomy but died within 14 days following initial
emergency laparotomy, patients were also determined as
having ‘ongoing infection needing relaparotomy’. ‘No ongo-
ing infection, not needing relaparotomy’ was defined as
patients who either underwent a relaparotomy for secondary
peritonitis yielding no residual infection or new pathology, or
patients who did not receive a relaparotomy and survived the
acute phase of the disease (at least 14 days). In-hospital death
was defined aspatientswho died during hospitalization, when
the initial operation for abdominal sepsis due to secondary
peritonitis was performed.
Data collection
Data were prospectively collected. Data on cultures of
abdominal fluid obtained at index laparotomy were evalu-
ated. Abdominal fluid cultures were not obtained system-
atically at index laparotomy. Other assessed data included:
patient characteristics, disease and operation related infor-
mation, and postoperative variables including the develop-
ment of major peritonitis-related complications for
12 months following index operation.
Microbial profiles
Patients were divided over five different microbial profiles
based on the spectrum reported in the culture results: (1) no
microbial growth, (2) coliform species (gram negative
microorganisms) in absence of gram positive species, (3)
gram positive cocci in absence of gram negative species,
(4) coliforms and positive cocci, and (5) only anaerobes.
Furthermore, patients with yeast (mono- or polymicrobial)
or with pseudomonas (mono- or polymicrobial) infections
were also identified. The latter two categories were not
mutually exclusive from the five main groups. These main
groups are considered relevant as literature describes
possible differences in outcome (in-hospital death) for
abdominal sepsis patients [18, 21–30].
Antibiotic regimen at the initial laparotomy
All patients received empirical antibiotic treatment at the
emergency laparotomy, covering gram positive cocci
(amoxicillin), gram negative rods (gentamicin) and anae-
robes (metronidazole). This broad spectrum abdominal
flora coverage is considered to be adequate in light of
resistance patterns in more than 95% of cases in a study of
microbial resistance patterns of our country [30]. Notewor-
thy, resistance of gram negative microorganisms to amox-
icillin is only seen occasionally in our country, certainly in
community-acquired peritonits [30]. Gentamicin dosage
(4 mg/kg) was systematically monitored by obtaining
“peak” and “trough” levels when administrated more than
3 days. Dosing was adjusted according to levels measured
and in case of (preexistent) renal dysfunction.
Antibiotic susceptibility tests were performed on all
obtained isolates, in order to identify the efficiency of the
empiric antibiotic regime.
Statistical analysis
Demographic data and baseline characteristics were com-
pared for patients with ‘ongoing infection needing relapar-
otomy’ and ‘no ongoing infection, relaparotomy not
needed’ as well as for patients that died in-hospital and
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outcomes of ‘ongoing infection needing relaparotomy’ and
of in-hospital death. The culture results were also compared
between nosocomial (post-operative intra-abdominal infec-
tion) and community-acquired peritonitis (intra-abdominal
infection at presentation on the Emergency Department).
Continuous variables were expressed as medians with
associated 25–75% interquartile ranges and compared using
Mann-Whitney U tests. Categorical numbers were reported
as absolute numbers (frequencies with percentages) and
compared using a χ
2 test. In hypothesis testing, p-values
of <0.05 were considered significant.
Whether or not a certain microbial profile was predictive
for either ongoing infection needing relaparotomy or in-
hospital death was evaluated by univariate analyses. A P-
value <0.10 was considered to depict association with the
evaluated outcome variable. In case of a univariate
association, a multivariate regression analysis was per-
formed to evaluate if there was an independent association.
All statistic analyses were performed using SPSS for
Windows version 18 (SPSS® Inc, Chicago, Illinois).
Results
Patient inclusion and demographic data
In total 229 of the 510 eligible secondary peritonitis
patients were included and randomized in the RELAP trial,
to either an on-demand strategy (n= 1 1 4 )o ra‘planned
strategy' (n=115; Fig. 1). Tables 1 and 2 present the
demographic and baseline characteristics for both all
included patients (n=229) and patients with culture results
available (n=158). Patients with ‘ongoing infection needing
a relaparotomy’ (overall n=78, cultures available n=49)
and patients with ‘no ongoing infection, not needing
relaparotomy’ were compared in Table 1. Patients that died
in-hospital (overall n=50, cultures available n=31) were
compared to those who survived the initial hospital
admission (overall n=179, cultures available n=127) in
Table 2.
Culture results
Abdominal fluid from the index laparotomy was cultured in
69% of patients (n=158, Fig. 1). In 110 out of 158 (70%)
patients more than one species were cultured (polymicro-
bial) at initial emergency laparotomy, while in 30 out of 158
(19%) patients one single strain of microorganisms (mono-
microbial) was cultured (Table 3). Only 18 out of 158
cultures showed no microbial growth (11%).
Patients were divided over the five clinically relevant
microbial categories according to culture results, including
the group with negative culture results. Forty-one patients
(25%) had coliforms without gram positive species, 18
patients (11%) had gram positive cocci without gram
negative species, 73 patients (46%) had both coliforms
and gram positive cocci and five patients (3%) had
anaerobes only (Fig. 1). In addition, 35 patients (22%)
had yeast-positive cultures (3 patients monomicrobial
yeast), while 13 patients (8%) were positive for Pseudo-
monas aeruginosa (1 patient monomicrobial; Fig. 1).
Overall Escherichia coli was most frequently cultured (85
strains), followed by Enterococcus species (65 strains). A
complete overview of cultured micro-organisms is pre-
sented in Table 3.
Susceptibility results of cultures obtained at the initial
laparotomy were available for 116 patients (83%). Overall
resistance against antibiotics used as empiric regimen is
depicted in Table 4. Resistance of Enterococcus species
against amoxicillin specifically was 11% (11/99), whereas
as much as 82% (61/99) of strains showed multidrug
resistance. Regarding the ‘positive cocci only’ group 35%
(6/17) of patients had strains resistant against amoxicillin.
In the group where positive cocci and coliforms were
cultured this resistance was only present in 8% (5/62) of
patients. Gentamicin resistance of coliform strains was 3%
(4/133) whereas 76% (101/133) of strains were multidrug
resistant. Three of 14 (21%) strains with Pseudomonas
showed multidrug resistance.
Outcome
In total, 78 out of 229 (34%) patients had ‘ongoing
infection needing a relaparotomy’ and 50 out of 229
(22%) patients died in-hospital. When patients with cultures
available were compared to those without cultures, compa-
rable proportions of patients with ‘ongoing infection
needing relaparotomy’ (with culture 49/158, 31% vs.
without culture 29/71, 41%, P=0.13) and comparable
proportions of patients who died in-hospital (with culture
31/158, 20% vs. without culture 18/71, 26%, P=0.32) were
seen. As can be expected, mortality was higher in the group
with ongoing infection (35% vs. 15% for all patients and
27% vs. 17% for those with available culture results;
Table 1). Poly- and monomicrobial growth was seen in
comparable proportions of patients with or without ongoing
infection and of patients who did or did not survive
(Tables 5 and 6).
Predictive value of microbial profile
‘Ongoing infection needing relaparotomy’
No microbial profile cultured from abdominal fluid samples
at the initial emergency laparotomy was associated with
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growth was associated with a lower rate of ongoing
abdominalinfectionneedingrelaparotomy,ascanbeexpected
(OR 0.25, 95%CI 0.06–1.12, P=0.070). Furthermore, resis-
tance to the empiric therapy of gram positive cocci and
coliforms was associated with ongoing infection (OR 3.27,
95%CI 0.94–11.45, P=0.063 and OR 7.83, 95%CI 0.79–
77.78, P=0.079). These variables were entered in a multivar-
iate regression model along with perforation or ischemia as
the cause of abdominal sepsis because this was less frequent
in patients with ongoing infection. The multivariate analysis
showed that although not statistically significant, there was a
strong independent association of amoxicillin resistant gram
positive cocci (OR 3.43, 95%CI 0.95–12.38, P=0.060) and
gentamicin resistant coliforms (OR 7.61, 95%CI 0.75–76.94,
P=0.085) with ongoing infection.
In-hospital death
Monoculture of gram positive cocci in the abdominal fluid
at the initial emergency laparotomy was highly associated
with in-hospital death (OR 4.08, 95%CI 1.5–11, P=.008).
Other microbial profiles were not clearly associated with in-
hospital death (Table 6). Looking closer at patients with
only gram positive cocci, no major differences were seen in
severity of disease and baseline peritonitis characteristics
compared to the other patients. We did find, however, that a
large proportion (72%) underwent surgery for peritonitis
due to a perforation (Table 7). Moreover, more patients with
only gram positive bacteria had an upper gastrointestinal
(GI) source of peritonitis compared to patients with other
bacterial profiles (44% versus 21%). Although patients with
gram positive bacteria only showed high rates of resistance
to empiric therapy, this was not associated with death.
Multivariate analysis was performed to determine
whether gram positive cocci were independently associated
with mortality. The variables ‘gram positive cocci only’
(yes/no), severity of disease (APACHE-II score), upper GI
perforation (yes/no), community-acquired (yes/no) and age
were entered into the model. Community-acquired perito-
nitis (OR 5.57, 95%CI 1.68–18.47, P=.0.005) and
APACHE-II score (OR 1.22 per point increase, 95%CI
1.10–1.36, P<.0.001) were independently associated with
in-hospital death. Monoculture of gram positive cocci (OR
3.7, 95%CI 0.99–13.8, P=.0.021) was borderline associated
with in-hospital death.
Univariate analysis showed there was no association of
amoxicillin resistant gram positive cocci and in-hospital
death (OR 1.63, 95%CI 0.40–6.26, P=0.494) despite the
independent association with ongoing infection.
Fig. 1 Flow chart of patient
inclusion and overall culture
results per microbial profile
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The similar distribution of micro-organisms between
community-acquired and nosocomial peritonitis (Table 3)
is also reflected by comparable microbial profiles (Table 8).
The finding that community-acquired peritonitis is an
independent predictor of death is reflected in significant-
ly more patients with community-acquired peritonitis
who died in-hospital (31% vs. 6%, P<.0.001). However,
since there is a similar distribution of the microbial
profiles, other factors in community-acquired peritonitis
were examined. Initial severity of disease was somewhat
more profound for the community-acquired peritonitis
group (APACHE-II score 16 [IQR 12–20] vs. nosocomial
14 [IQR 12–16], P=.0.075). On the other hand, just the
same proportion of patients with community-acquired
peritonitis and nosocomial peritonitis needed a relaparot-
omy for ongoing infection (31%; Table 8).
Table 1 Demographic and clinical characteristics compared for patients with ‘ongoing infection needing relaparotomy’ and patients with ‘no
ongoing infection, not needing relaparotomy’
Variables Ongoing infection needing
relaparotomy
No ongoing infection, not
needing relaparotomy
P values for available
cultures
All
(N=78)
Cultures available
(n=49)
All
(N=151)
Cultures available
(n=109)
Age (years), median (IQR) 67 (56–73) 65 (55–73) 70 (57–76) 69 (57–76) 0.182
Male 43 (55%) 28 (43%) 66 (44%) 49 (45%) 0.156
Major comorbidity present, no. (%) 48 (62%) 29 (59%) 88 (58%) 63 (58%) 0.870
Malignancy 22 (28%) 14 (29%) 35 (23%) 25 (23%) 0.447
Cardiovascular disease 19 (24%) 15 (31%) 35 (23%) 27 (25%) 0.442
Respiratory disease (COPD) 9 (12%) 3 (6%) 22 (15%) 14 (13%) 0.207
Renal disease 8 (10%) 7 (14%) 9 (6%) 4 (4%) 0.044
Diabetes 6 (8%) 2 (4%) 14 (9%) 12 (11%) 0.156
Severity of disease
APACHE II score at study entry, median (IQR) 15 (13–18) 15 (12–19) 15 (13–18) 15 (13–18) 0.812
Etiology of peritonitis, no. (%) 0.048
Perforation 40 (51%) 27 (55%) 93 (62%) 67 (62%)
Anastomotic leakage 23 (30%) 13 (27%) 40 (27%) 29 (27%)
Ischemia 3 (4%) 1 (2%) 11 (7%) 9 (8%)
Inflammation 5 (6%) 3 (6%) 4 (3%) 2 (2%)
Other
a 7 (9%) 5 (10%) 3 (2%) 2 (2%)
Nosocomial (postoperative) peritonitis 37 (47%) 22 (45%) 71 (47%) 48 (44%) 0.920
Localization 0.972
Upper GI tract (incl. small bowel) 19 (24%) 10 (20%) 39 (26%) 28 (26%)
Lower GI tract 51 (65%) 33 (67%) 100 (66%) 71 (65%)
Biliary tract 6 (8%) 4 (8%) 8 (5%) 6 (6%)
Other
b 2 (3%) 2 (4%) 4 (3%) 4 (4%)
In-hospital mortality 27 (35%) 13 (27%) 23 (15%) 18 (17%) 0.143
Type of contamination 0.300
Clear 4 (5%) 0 (0%) 10 (7%) 5 (5%)
Turbid/cloudy 19 (24%) 11 (22%) 28 (19%) 23 (21%)
Purulent 24 (31%) 14 (29%) 51 (34%) 39 (36%)
Fecal 30 (38%) 23 (47%) 56 (37%) 37 (34%)
Bile 1 (1%) 1 (2%) 6 (4%) 5 (5%)
a‘Other’ consisted of 8x no evident infectious focus in contaminated abdomen, 1x bile leakage, 1x infected haematoma
b‘Other’ consisted of either an infectious focus localized at the upper as well as the lower GI tract or at a gynecologic site.
All continuous data are analyzed with the Mann Whitney-U test
All categorical data are analyzed with the Chi square test
IQR interquartile range
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In this study culture results from the initial emergency
laparotomy of secondary peritonitis patients were studied
for their microbial patterns as well as for their effect on
ongoing abdominal infection and on in-hospital death.
Patients participated in a randomized trial to evaluate
effectiveness of two surgical treatment strategies. In a large
proportion of patients (31%) no abdominal cultures were
drawn at initial surgery. Surgeons were blinded for the
allocated surgical treatment strategy at the time of the initial
laparotomy [12]. This would eliminate selection bias in
retrieval of fluid samples for culture merely related to
whether or not a relaparotomy would follow. Nevertheless,
macroscopic appearance of the abdominal contamination or
source of infection might have been reason for selection of
patients needing cultures. This bias can work in either
direction: some surgeons might feel that cultures might be
superfluous in clear-cut fecal contamination due to anasto-
motic leakage, whereas others might anticipate different
microorganisms in nosocomial peritonitis resulting in a
higher tendency to culture. No differences were found in
Table 2 Demographic and clinical characteristics compared for patients with in-hospital death and patients who survived the first hospital
admission
Variables In-hospital death Survival P values for available
cultures
All
(N=50)
Cultures available
(n=31)
All
(N=179)
Cultures available
(n=127)
Age (years), median (IQR) 73 (68–77) 74 (67–78) 66 (55–73) 64 (55–75) 0.004
Male 21 (42%) 15 (48%) 88 (49%) 62 (49%) 0.966
Major comorbidity present, no. (%) 31 (62%) 17 (55%) 105 (59%) 75 (59%) 0.670
Malignancy 11 (22%) 6 (19%) 46 (26%) 33 (26%) 0.443
Cardiovascular disease 9 (18%) 7 (23%) 45 (25%) 35 (28%) 0.574
Respiratory disease (COPD) 14 (28%) 7 (23%) 17 (9%) 10 (8%) 0.018
Renal disease 8 (16%) 0 (0%) 9 (5%) 1 (1%) 0.009
Diabetes 2 (4%) 1 (3%) 18 (10%) 13 (10%) 0.218
Severity of disease
APACHE II score at study entry, median (IQR) 19 (16–24) 20 (16–24) 14 (12–17) 14 (12–17) <0.001
Etiology of peritonitis, no. (%) 0.029
Perforation 34 (68%) 25 (81%) 99 (55%) 69 (54%)
Anastomotic leakage 7 (14%) 2 (6%) 56 (31%) 40 (31%)
Ischemia 6 (12%) 3 (10%) 8 (4%) 7 (6%)
Inflammation 1 (2%) 0 (0%) 8 (4%) 5 (4%)
Other
a 2 (4%) 1 (3%) 8 (4%) 6 (5%)
Nosocomial (postoperative) peritonitis 14 (28%) 4 (13%) 94 (53%) 66 (52%) <0.001
Localization 0.500
Upper GI tract (incl small bowel) 15 (30%) 10 (32%) 43 (24%) 28 (22%)
Lower GI tract 34 (68%) 20 (65%) 117 (65%) 81 (64%)
Biliary tract 1 (2%) 1 (3%) 13 (7%) 9 (7%)
Other
b 0 (0%) 0 (0%) 6 (3%) 6 (5%)
Type of contamination 0.697
Clear 5 (10%) 1 (3%) 9 (5%) 4 (3%)
Turbid/cloudy 9 (18%) 7 (23%) 38 (21%) 27 (21%)
Purulent 17 (34%) 10 (32%) 58 (32%) 43 (34%)
Fecal 17 (34%) 11 (35%) 69 (39%) 49 (39%)
Bile 2 (4%) 2 (6%) 5 (3%) 4 (3%)
a‘Other’ consisted of 8x no evident infectious focus in contaminated abdomen, 1x bile leakage, 1x infected haematoma
b‘Other’ consisted of either an infectious focus localized at the upper as well as the lower GI tract or at a gynecologic site
All continuous data are analyzed with the Mann Whitney-U test
All categorical data are analyzed with the Chi square test
IQR interquartile range
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nosocomial peritonitis versus community-acquired peritonitis
Microbes Mono-microbial
a Poly-microbial
b Nosocomial
c Community-acquired
d Total number of isolates
Gram (−) rods (coliforms)
E. coli 10 75 42 43 85
Klebsiella pneumoniae 11 6 8 9 1 7
Enterobacter cloacae 11 2 9 4 1 3
Proteus mirabilis 01 0 4 6 1 0
Gram (−) rods not specified 3 6 5 4 9
Klebsiella oxytoca 18 4 5 9
Citrobacter freundii 07 2 5 7
Morganella (proteus) morganii 04 2 2 4
Serratia marcescens 02 2 0 2
Acinetobacter, not specified 0 1 1 0 1
Citrobacter amalonaticus 01 1 0 1
Hafnia alfeii 01 1 0 1
Proteus vulgaris 01 1 0 1
Subtotal 16 144 82 78 160
Gram (+) cocci
Enterococci, not specified 6 59 39 26 65
Enterococcus faecalis 21 1 7 6 1 3
Streptococci viridans 01 2 4 8 1 2
Streptococcus milleri 01 3 4 7
Coagulase negative Staphylococci 0 7 3 4 7
Streptococci, not specified 0 3 1 2 3
Staphylococcus hemolyticus 02 2 0 2
Staphylococci not specified 0 2 0 2 2
Stapgylococcus aureus 01 0 1 1
Streptococci (Group B) 0 1 0 1 1
Streptococcus constellatus 01 0 1 1
Subtotal 8 106 59 55 114
Anaerobes
Anaerobes not further specified 2 46 25 23 48
Bacteroides fragilis 16 1 6 7
Bacillus not specified 1 3 3 1 4
Bacteroides vulgaris 02 1 1 2
Bacteroides ovatus 10 1 0 1
Bacteroides difteroides 01 1 0 1
Clostridium septicum 01 0 1 1
Subtotal 5 59 32 32 64
Yeast
Yeast not further specified 2 16 9 9 18
Candida albicans 21 1 5 8 1 3
Candida glabrata 03 1 2 3
Candida tropicalis 01 0 1 1
Subtotal 4 31 15 20 35
Pseudomonas
Pseudomonas aeruginosa 11 3 5 9 1 4
Total 34 353 193 194 387
aIn 36 patients
bIn 104 patients
cIn 70 patients
dIn 88 patients
Eur J Clin Microbiol Infect Dis (2012) 31:671–682 677demographic and clinical characteristics, showing that
potential selection bias did not affect distribution of patients
in the cultured group versus the total trial cohort.
Culture results from the initial emergency laparotomy
revealed a large contribution of gram positive cocci as
infectious agent. In more than half of the patients (58%)
gram positive species were retrieved, with or without
presence of other microorganisms. As can be expected,
the absence of microbial growth was associated with a
lower rate of ongoing infection. Nevertheless, these patients
did have peritonitis at index operation, predominantly
caused by perforation or anastomotic leakage (14 out of
18 patients without microbial growth). Furthermore, a
larger proportion of patients with ongoing infection needing
relaparotomy exhibited amoxicillin resistant positive cocci
and gentamicin resistant coliforms. Although a significant
association could not be determined, it can be argued that
these results are indeed clinically relevant. On the other
hand, results are based on sub analyses and therefore study
numbers were small and probably under powered.
Secondary peritonitis caused by gram positive cocci,
predominantly Entercoccus spp., in the absence of gram
negative microorganisms was associated with in-hospital
death. This association appears to be very relevant for
clinical practice. Resistance to empiric therapy was associ-
ated with ongoing infection, but this resistance was not
associated with increased risk of in-hospital death. Possibly
the current sample size limits the capacity to determine this
association. There is evidence that suggests that complicat-
ed intra-abdominal infections involving mixed flora can be
Table 5 Predictive value of microbial profile for ‘ongoing infection needing relaparotomy’ in patients with culture available from index
laparotomy (n=158)
Analysis Ongoing infection needing relaparotomy
(N=49)
No ongoing infection, not needing relaparotomy
(N=109)
OR 95% CI P
Univariate analysis
Monomicrobial
a 11 (23%) 19 (20%) 0.84 0.36–1.5 0.686
Microbial profile
Negative culture result 2 (4%) 16 (15%) 0.25 0.06–1.12 0.070
Coliform 12 (25%) 29 (27%) 0.90 0.41–1.95 0.779
Gram (+) cocci 6 (12%) 12 (11%) 1.13 0.40–3.20 0.821
Coliforms and gram (+) cocci 26 (53%) 47 (43%) 1.49 0.76–2.94 0.247
Only anaerobes 2 (4%) 3 (3%) 1.50 0.24–9.30 0.661
Yeast present 10 (20%) 25 (23%) 0.86 0.38–1.97 0.724
Pseudomonas present 2 (4%) 11 (11%) 0.38 0.08–1.78 0.219
Amoxicilline resistant gram (+) cocci
b 6 (15%) 5 (5%) 3.27 0.94–11.45 0.063
Gentamicin resistant coliforms
b 3 (8%) 1 (1%) 7.83 0.79–77.78 0.079
Multi drug resistance
b 31 (79%) 63 (66%) 1.36 0.60–3.06 0.465
Multivariate analysis
b
Negative culture result 2 (5%) 16 (17%) 0.29 0.06–1.35 0.189
Amoxicilline resistant gram (+) cocci 6 (15%) 5 (5%) 3.43 0.95–12.38 0.060
Gentamicin resistant coliforms 3 (8%) 1 (1%) 7.61 0.75–76.94 0.085
Perforation or ischemia 23 (59%) 65 (68%) 0.67 0.30–1.52 0.342
OR odds ratio, CI confidence interval
a Regression analysis in 140 patients with positive culture result (47 ongoing infection, 93 no ongoing infection), since patients without growth
are in neither of the categories.
b Regression analysis in 134 patients with known susceptibility or negative culture result (39 ongoing infection, 95 no ongoing infection).
Table 4 Overall resistance for microbial subgroups specified for empiric regimen and multidrug resistance where antibiotic susceptibility is
known (284 strains in 116 patients)
Microbial group Amoxicillin Gentamicin Metronidazol Multidrug resistance
a
Positive cocci 11% (11/99) n.a. n.a. 62% (61/99)
Coliforms n.a. 3% (4/133) n.a 76% (101/133)
Anaerobes n.a. n.a. 0% (0/52) 21% (11/52)
a Resistance for more then one antibiotic
n.a. not applicable
678 Eur J Clin Microbiol Infect Dis (2012) 31:671–682Table 7 Disease characteristics comparing patients with only gram positive cocci (n=18) to those with other cultured micro-organisms (n=140)
from index laparotomy (n=158)
Variables Only gram (+) cocci Others P value
N=18 N=140
Severity of disease
APACHE II score at study entry, median (IQR) 17 (13–20) 15 (12–17) 0.178
Etiology of peritonitis, no. (%) 0.485
Perforation 14 (78%) 80 (57%)
Anastomotic leakage 3 (17%) 39 (28%)
Ischemia 1 (6%) 9 (6%)
Inflammation 0 (0%) 5 (4%)
Other
a 0 (0%) 7 (5%)
Nosocomial (postoperative) peritonitis 6 (33%) 64 (46%) 0.320
Localization 0.454
Upper GI tract (incl. small bowel) 8 (44%) 30 (21%)
Lower GI tract 9 (50%) 95 (68%)
Biliary tract 1 (6%) 9 (6%)
Other
b 0 (0%) 6 (4%)
Amoxicilline resistance
c 6 (35%) 5 (4%) <0.001
a‘Other’ consisted of 8x no evident infectious focus in contaminated abdomen, 1x bile leakage, 1x infected haematoma
b‘Other’ consisted of either an infectious focus localized at the upper as well as the lower GI tract or at a gynecologic site.
c In 134 patients with known susceptibility or negative culture result (n=17 only gram positive cocci profile, n=117 other profiles)
Continuous data were analyzed with the Mann Whitney U-test. All categorical data were analyzed with the chi-square test
IQR interquartile range
Table 6 Predictive value of microbial profile for in-hospital death in patients with culture available from index laparotomy (n=158)
Analysis In-hospital death (N=31) Survival (N=127) OR 95% CI P
Univariate analysis
Monomicrobial
a 7 (23%) 23 (18%) 1.29 0.49–3.40 0.607
Microbial profile
Negative culture result 3 (10%) 15 (12%) 0.80 0.22–2.96 0.738
Coliforms 6 (19%) 35 (28%) 0.60 0.22–1.61 0.310
Gram (+) cocci 8 (26%) 10 (8%) 4.08 1.43–11.61 0.008
Coliforms and gram (+) cocci 12 (39%) 61 (48%) 0.63 0.27–1.45 0.274
Only anaerobes 1 (3%) 4 (3%) 1.00 0.1–9.3 1.000
yeast present 8 (26%) 27 (21%) 1.26 0.50–3.18 0.626
Pseudomonas present 2 (6%) 11 (9%) 0.71 0.15–3.39 0.664
Amoxicilline resistant gram (+) cocci
b 3 (12%) 8 (7%) 1.63 0.40–6.26 0.494
Gentamicin resistant coliforms
b 1 (4%) 3 (3%) 1.40 0.14–14.03 0.775
Multi-drug resistance
b 18 (69%) 76 (70%) 0.91 0.35–2.23 0.830
Multivariate analysis
Gram (+) cocci 8 (26%) 10 (8%) 3.69 0.99–13.80 0.052
APACHE II score, median (IQR) 20 (16–24) 14 (12–17) 1.22 1.10–1.36 <0.001
Community-acquired 27 (87%) 61 (48%) 5.57 1.68–18.47 0.005
Upper GI perforation 8 (26%) 16 (13%) 2.06 0.60–7.06 0.253
Age, median (IQR) 74 (67–78) 64 (55–75) 1.04 1.00–1.0 0.069
OR odds ratio, CI confidence interval
a Regression analysis in 140 patients with positive culture result (28 in-hospital death, 112 survival), since patients without growth are in neither
of the categories
b Regression analysis in 134 patients with known susceptibility or negative culture result (26 in-hospital death, 108 survival)
Eur J Clin Microbiol Infect Dis (2012) 31:671–682 679treated with surgery and non-enterococcal antibiotic cover-
age [22]. However, in settings without routine empiric
coverage of enterococci, enterococcal infections are associ-
ated with a higher mortality [22]. Patients in our study all
received empiric coverage of Enterococcus spp. by amox-
icillin. The high prevalence of Enterococcus spp. and the
reported higher mortality due to Enterococcus spp. suggests
benefit from empiric coverage. The regimen used should
take into account regional resistance patterns, including
resistance to amoxicillin of gram negative microorganisms.
In our hospital and for this study suitability of empirical
antibacterial treatment was based on national resistance
surveillance data [30]. In the Nethmap database nationwide
microbial resistance patterns are evaluated, a surveillance
that is performed yearly. Based on these data coverage of
empiric therapy consisting of amoxicillin, gentamicin and
metronidazole should have been appropriate in the vast
majority of cases. Resistance of Enterococcus spp. against
amoxillin in this study, however, surprisingly exceeded
regional prevalence.
We can conclude, based only on present results, that
amoxicillin coverage may be insufficient in these severely
ill patients. Importantly, in our setting vancomycin resistant
Enterococcus spp. are rare (sporadic encounter, 0% www.
swab.nl) and vancomycin is not part of empiric therapy.
Yeast strains are common in early severe secondary
peritonitis (22%), but not clearly related to mortality in this
cohort of patients. Patients did not receive prophylactic or
preemptive antifungal therapy, but were treated in case of
clinically suspected or confirmed invasive candidiasis. The
absence of any relation between yeast in polymicrobial
infection and death is not likely caused by a lack of
prophylaxis. A recent systematic review of prospective
trials evaluating single drug antifungal prophylaxis, dem-
onstrates that prophylaxis is not as effective for surgical
patients as opposed to medical patients [31]. These results
and presented data do not support the view to broaden the
empiric regimen with coverage of yeast in patients with
peritonitis. Also, empiric coverage of Pseudomonas aeru-
ginosa can not be propagated based on present results.
Pseudomonas is a notorious hospital microbe, opportunistic
and resistant to many antibiotics [32]. Here, prevalence of
Pseudomonas was similar among survivors and nonsurvi-
vors, and surprisingly not more frequent in nosocomial
Table 8 Outcomes comparing patients with nosocomial (n=108) peritonitis versus community-acquired (n=121) peritonitis
Variables Nosocomial peritonitis Community-acquired
peritonitis
P values for available
cultures
All
(N=108)
Cultures available
(N=70)
All
(N=121)
Cultures available
(N=88)
Severity of disease
APACHE II score at study entry, median (IQR) 14 (13–16) 14 (12–16) 16 (13–20) 16 (12–20) 0.075
Primary outcomes
Ongoing infection needing relaparotomy 37 (34%) 22 (31%) 41 (34%) 27 (31%) 0.920
In-hospital death 14 (13%)
a 4 (6%) 36 (30%)* 27 (31%) <0.001
Cultures
Monomicrobial 12 (17%) 18 (20%) 0.478
Microbial profile
Negative culture results 6 (9%) 12 (14%) 0.320
Coliforms 18 (26%) 23 (26%) 0.952
Gram (+) cocci 6 (9%) 12 (14%) 0.320
Coliforms and gram (+) cocci 39 (56%) 34 (39%) 0.032
Only anaerobes 1 (1%) 4 (5%) 0.266
Yeast present 15 (21%) 20 (23%) 0.845
Pseudomonas present 5 (7%) 8 (9%) 0.658
Amoxicilline resistant gram (+) cocci
b 5 (9%) 6 (10%) 0.891
Gentamicin resistant coliforms
b 2 (4%) 2 (3%) 0.916
Multi-drug resistance
b 50 (91%) 44 (72%) 0.001
aP=0.002 (all patients)
b In 134 patients with known susceptibility or negative culture result (n=61 nosocomial peritonitis, n=73 community-acquired peritonitis)
Continuous data were analyzed with the Mann Whitney U-test. All categorical data were analyzed with the chi-square test
IQR interquartile range
680 Eur J Clin Microbiol Infect Dis (2012) 31:671–682peritonitis than in community-acquired peritonitis for early
disease.
Furthermore, nosocomial peritonitis was associated with
similar proportions of patients with yeast or Pseudomonas
spp. as was community-acquired peritonitis. Nosocomial
infection is often associated with other types of pathogens
than community-acquired infection. This is well-known for
pneumonia [33]. It is likely that during initial disease, be it
an anastomotic leakage (nosocomial) or perforated diver-
ticulitis (community-acquired), the abdominal invasion of
abundantly available enteric bacteria is quite similar.
Therefore, when empiric antibiotic coverage is adequate
and frequently evaluated by local resistance surveillance,
cultures of abdominal fluid during initial laparotomy may
not contribute to clinical management decisions in the
individual patient.
In conclusion, in this study on secondary peritonitis no
microbial profile was associated with ongoing infection
needing a relaparotomy except for a negative culture result.
Although not statistically significant, the association be-
tween resistance to empiric therapy and ongoing infection
compels more attention to be paid to resistance in the
selection of empiric antibiotic coverage. Present data do not
support empiric coverage of yeast and Pseudomonas spp. in
abdominal sepsis. Gram positive cocci, in particular
Enterococcus spp., appeared to be a larger threat to
peritonitis patients than previously assumed.
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